DURHAM, N.C., April 22, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the company has begun shipping its newly formulated Dermacyte™ Oxygen Concentrate to customers who pre-ordered this revolutionary beauty and skin care product on-line. Beginning this week, there is no longer a waiting period for order fulfillment and customers can select a shipping time-frame such as 3-5 days, or 1-2 days. Shipping rates will vary accordingly. Retail orders can be placed on the newly designed secure website at www.BuyDermacyte.com.
"Preorder sales for Dermacyte Oxygen Concentrate are encouraging and many orders are from repeat customers who purchased our product last fall during the market testing phase," said Chris Stern, company chairman and CEO. "The product now being shipped has an improved formulation and shows the new brand design and packaging that future Dermacyte products will feature, most notably the eye cream that we expect to introduce this summer."
Dermacyte Oxygen Concentrate is a scientifically designed, proprietary concentrate designed to enhance oxygen delivery to skin. It is the first product in a broad and diverse cosmetic line currently under development by the Oxygen Biotherapeutics. It uses our patented Oxycyte Technology, scientifically designed to enhance oxygen delivery to tissues, such as skin. Some potential benefits of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.
Oxygen is essential for radiant, young-looking skin. It assists in the production of collagen and elastin, as well as with skin repair and regeneration. As we age, the body's ability to deliver oxygen to dermal tissue deteriorates. A lack of oxygen at the cellular level can cause skin to age prematurely, increasing the appearance of fine lines and age spots, making skin look dry and dull. A boost in oxygen may enhance the overall appearance and feel of your skin, leaving it smoother and healthier-looking.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte™ that is being formulated for both intravenous and topical delivery for conditions including but not limited to traumatic brain injury, decompression sickness and topical wounds, as well as for personal skin care. More information is available at www.oxybiomed.com.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for the expansion of the Dermacyte product line and the timing of the introduction of those new products. Matters beyond the company's control could lead to delays in the new product introductions and customer acceptance of these new products. Furthermore, there can be no assurance that such plans will lead to meaningful sales of Dermacyte or generate any revenue for the company. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.